This activity is jointly provided by AMCP and Medscape Oncology.
AMCP and Medscape Oncology recently launched “A Value-Based Framework in the Clinical Integration of PARP Inhibitors in the Management of Ovarian Cancer,” featuring Dr. Kathleen Moore and Dr. Bradley Monk. This activity focuses on the clinical utility of PARP inhibitors in ovarian cancer, considerations for balancing efficacy and safety in clinical practice, and the important role of the managed care pharmacists and clinical pharmacists in optimizing the patient's outcome
This activity is designed for managed care pharmacists, clinical pharmacists, and oncologists.
Participants who complete this activity will:
- Have increased knowledge regarding the
- Clinical role of PARP inhibitors in the management of advanced OC
- Cost-effectiveness analyses and pharmacoeconomic data on PARP inhibitor therapy for OC
- Demonstrate greater confidence in their ability to utilize roles of the healthcare team for optimizing PARP inhibitor therapy in the management of patients with advanced OC
Value-Based Framework in the Clinical Integration of PARP Inhibitors in the Management of Ovarian Cancer
Authors: Kathleen N. Moore, MD; Bradley Monk, MD, FACOG, FACS; Stephanie L. Ho, PharmD, BCPSF
CME / ABIM MOC / CE Released: 10/4/2021
Valid for credit through: 10/4/2022